AR110443A1 - Inhibidores de histona metiltransferasas - Google Patents
Inhibidores de histona metiltransferasasInfo
- Publication number
- AR110443A1 AR110443A1 ARP170103662A ARP170103662A AR110443A1 AR 110443 A1 AR110443 A1 AR 110443A1 AR P170103662 A ARP170103662 A AR P170103662A AR P170103662 A ARP170103662 A AR P170103662A AR 110443 A1 AR110443 A1 AR 110443A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- heteroalkyl
- halo
- alkoxy
- haloalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Abstract
Compuestos tricíclicos angulares que son inhibidores de las histona metiltransferasas G9a y/o GLP, y por ello son de utilidad para el tratamiento de enfermedades que son tratables por la inhibición de G9a y/o GLP, tales como cánceres y hemoglobinopatias (por ejemplo, b-talasemia y enfermedad de células falsiformes). También se proveen composiciones farmacéuticas que contienen dichos compuestos. Reivindicación 1: Un compuesto de la fórmula (1), donde: Z¹ y Z² son de manera independiente C (cuando R² o R³ está unido al mismo), CH o N; alk es alquileno en donde uno o dos átomos de carbono de la cadena alquileno están reemplazados opcionalmente por NR, O, S o SO₂ (donde R es hidrógeno o alquilo), y la cadena alquileno está sustituida opcionalmente con uno o dos sustituyentes seleccionados de manera independiente entre halo, haloalquilo, haloalcoxi, hidroxi y alcoxi, y en donde -alk-R¹ está unido al carbono (a) o (b); R¹ es -NR⁶R⁷ (donde R⁶ y R⁷ son de manera independiente hidrógeno, alquilo, hidroxialquilo, alcoxialquilo, haloalquilo o haloalcoxialquilo), heterociclilo no sustituido, heterociclilo sustituido con 1, 2 ó 3 de Rᵃ, Rᵇ, y Rᶜ, en donde Rᵃ, Rᵇ y Rᶜ se seleccionan de manera independiente entre alquilo, hidroxi, alcoxi, halo, haloalquilo, alquilcarbonilo y haloalquilcarbonilo, o espiroheterocicloamina en donde un átomo de nitrógeno de la espiroheterocicloamina está unido a alk; R² es hidrógeno, alquilo, cicloalquilo, halo, hidroxi, alcoxi, haloalcoxi o ciano; R³ es hidrógeno, alquilo, halo, alcoxi, alquilamino, dialquilamino o ciano; R⁴ es hidrógeno, deuterio, alquilo (opcionalmente sustituido con uno a nueve deuterios), cicloalquilo (opcionalmente sustituido con uno o dos sustituyentes seleccionados de manera independiente entre alquilo, hidroxi, halo, alcoxi, haloalquilo, y haloalcoxi), cicloalquenilo, fenilo (opcionalmente sustituido con uno o dos sustituyentes seleccionados de manera independiente entre alquilo, halo, hidroxi y alcoxi), heteroarilo (opcionalmente sustituido con uno o dos sustituyentes seleccionados de manera independiente entre alquilo, halo, hidroxi y alcoxi), heterociclilo (opcionalmente sustituido con uno o dos sustituyentes seleccionados de manera independiente entre alquilo, halo, hidroxi, alcoxi, haloalquilo y haloalcoxi), -ORᵈ (donde Rᵈ es hidrógeno, alquilo, haloalquilo, hidroxialquilo, alcoxialquilo, cicloalquilo, halocicloalquilo, cicloalquilalquilo, arilo, aralquilo, heteroarilo, heteroaralquilo, heterociclilo o heterociclilalquilo), o NRᵉRᶠ (donde Rᵉ es hidrógeno o alquilo y Rᶠ es hidrogeno, alquilo, alquilo deuterado, alquiltioalquilo, acilo, haloalquilo, hidroxialquilo, alcoxialquilo, aminoalquilo, cianoalquilo, carboxialquilo, alcoxicarbonilalquilo, cicloalquilo, cicloalquilalquilo, arilo, aralquilo, heteroarilo, heteroaralquilo, heterociclilo o heterociclilalquilo), en donde el cicloalquilo, el arilo, el heteroarilo, y el heterociclilo ya sea solos o como parte del cicloalquilalquilo, aralquilo, heteroaralquilo y heterociclilalquilo en Rᵈ y Rᶠ de manera independiente no están sustituidos o están sustituido con 1, 2 ó 3 de Rᵍ, Rʰ y Rⁱ, en donde Rᵍ, Rʰ y Rⁱ se seleccionan de manera independiente entre alquilo, hidroxi, alcoxi, halo, haloalquilo, ciano, carboxi, alcoxicarbonilo y haloalcoxi, y en donde el alquileno del aralquilo, heteroaralquilo, heterociclilalquilo y cicloalquilalquilo en Rᵈ y Rᶠ está sustituido opcionalmente con uno a nueve deuterios; X es carbono o nitrógeno; y el anillo B es fenilo, heteroarilo de 5 ó 6 miembros que contiene uno, dos o tres heteroátomos seleccionados de manera independiente entre nitrógeno, oxigeno y azufre, cicloalquilo de 5 ó 6 miembros, espirocicloalquilo, espiroheterocicloamina o heterociclilo saturado de 5, 6 ó 7 miembros, en donde cada de uno de los anillos del anillo B no está sustituido o está sustituido con 1, 2, 3 ó 4 de Rʲ, Rᵏ, Rˡ y Rᵐ, en donde Rʲ, Rᵏ, Rˡ y Rᵐ se seleccionan de manera independiente entre alquilo, hidroxi, ciano, alcoxi, halo, haloalquilo y haloalcoxi; o una sal farmacéuticamente aceptable del mismo; y en donde el compuesto de la fórmula (1) no es: 5-aminobenzo[f][1,7]naftiridin-8-metanamina o 10-etoxi-8-(morfolinometil)-1,2,3,4-tetrahidrobenzo[h][1,6]naftiridin-5-ol; o una sal del mismo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662438121P | 2016-12-22 | 2016-12-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR110443A1 true AR110443A1 (es) | 2019-03-27 |
Family
ID=60972497
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP170103662A AR110443A1 (es) | 2016-12-22 | 2017-12-22 | Inhibidores de histona metiltransferasas |
Country Status (7)
Country | Link |
---|---|
US (2) | US10829452B2 (es) |
EP (2) | EP3558971B1 (es) |
JP (2) | JP7091336B2 (es) |
AR (1) | AR110443A1 (es) |
ES (1) | ES2910108T3 (es) |
TW (1) | TW201829386A (es) |
WO (1) | WO2018119208A1 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018119208A1 (en) * | 2016-12-22 | 2018-06-28 | Global Blood Therapeutics, Inc. | Histone methyltransferase inhibitors |
CN118021814A (zh) | 2017-04-21 | 2024-05-14 | Epizyme股份有限公司 | 用ehmt2抑制剂进行的组合疗法 |
CA3079412A1 (en) * | 2017-10-18 | 2019-04-25 | Epizyme, Inc. | Methods of using ehmt2 inhibitors in immunotherapies |
MA50417A (fr) * | 2017-10-18 | 2020-08-26 | Epizyme Inc | Procédés d'utilisation d'inhibiteurs de l'ehmt2 dans le traitement ou la prévention de troubles du sang |
CN111196817B (zh) * | 2018-11-19 | 2021-06-11 | 四川大学华西医院 | 作为brpf1抑制剂的三环化合物 |
US20220056043A1 (en) * | 2019-02-19 | 2022-02-24 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Nitrogen-containing fused cyclic compound, preparation method therefor and use thereof |
CN111620818B (zh) * | 2019-02-28 | 2023-09-29 | 暨南大学 | 8,9-二甲氧基啡啶类化合物及其应用 |
WO2022162471A1 (en) | 2021-01-27 | 2022-08-04 | Vandria Sa | Urolithin derivatives and methods of use thereof |
CN113004294B (zh) * | 2021-03-08 | 2023-01-17 | 温州大学新材料与产业技术研究院 | 一种四氢呋喃并1,4-二氢喹啉类化合物及其制备方法和应用 |
CN114573569B (zh) * | 2022-03-30 | 2023-07-04 | 邦恩泰(山东)生物医药科技集团股份有限公司 | 一种异喹啉类化合物的制备方法 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
AU3741801A (en) | 2000-03-15 | 2001-09-24 | Aventis Pharma Gmbh | Substituted beta-carbolines with ikb-kinase inhibiting activity |
EP1590348A1 (en) | 2002-12-20 | 2005-11-02 | 3M Innovative Properties Company | Aryl / hetaryl substituted imidazoquinolines |
NZ545412A (en) | 2003-08-27 | 2008-12-24 | Coley Pharm Group Inc | Aryloxy and arylalkyleneoxy substituted imidazoquinolines |
BRPI0414856A (pt) | 2003-10-03 | 2006-11-21 | 3M Innovative Properties Co | imidazoquinolinas alcóxi-substituìdas |
ES2475728T3 (es) | 2005-02-09 | 2014-07-11 | 3M Innovative Properties Company | Tiazoloquinolinas y tiazolonaftiridinas sustituidas con alcoxi |
JP5399905B2 (ja) | 2006-09-01 | 2014-01-29 | センワ バイオサイエンシズ インコーポレイテッド | セリン−トレオニンタンパク質キナーゼおよびparp調節因子 |
WO2008101682A2 (en) | 2007-02-22 | 2008-08-28 | Syngenta Participations Ag | Iminipyridine derivatives and their uses as microbiocides |
EP2231656A1 (en) | 2007-12-19 | 2010-09-29 | Amgen Inc. | Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors |
MY150481A (en) | 2008-03-03 | 2014-01-30 | Irm Llc | Compounds and compositions as tlr activity modulators |
GB2465405A (en) | 2008-11-10 | 2010-05-19 | Univ Basel | Triazine, pyrimidine and pyridine analogues and their use in therapy |
WO2010056038A2 (ko) * | 2008-11-11 | 2010-05-20 | 제일약품주식회사 | 신규한 트리시클릭 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 포함하는 약학적 조성물 |
HUE043536T2 (hu) | 2009-10-06 | 2019-08-28 | Millennium Pharm Inc | PDK1 inhibitorként alkalmazható heterociklusos vegyületek |
US20130231360A1 (en) | 2010-04-22 | 2013-09-05 | The Brigham And Women S Hospital, Inc. | Beta-Carbolines as Inhibitors of Haspin and DYRK Kinases |
WO2011161256A1 (en) | 2010-06-25 | 2011-12-29 | Facultes Universitaires Notre Dame De La Paix | Beta carboline derivatives useful in the treatment of proliferative disorders |
WO2012129344A1 (en) | 2011-03-23 | 2012-09-27 | Amgen Inc. | Fused tricyclic dual inhibitors of cdk 4/6 and flt3 |
KR101827444B1 (ko) | 2012-02-01 | 2018-02-08 | 제일약품주식회사 | 트리사이클로 유도체 화합물의 신규한 결정형 산부가염 또는 이의 수화물 및 이의 제조방법 |
US10662193B2 (en) | 2014-01-21 | 2020-05-26 | Ac Immune Sa | Carbazole and carboline compounds for use in the diagnosis, treatment, alleviation or prevention of disorders associated with amyloid or amyloid-like proteins |
US9284272B2 (en) * | 2014-03-28 | 2016-03-15 | Abbvie Inc. | Inhibitors of histone methyltransferase G9a |
US9840500B2 (en) | 2014-06-16 | 2017-12-12 | Fundación Para La Investigación Médica Aplicada | Compounds as dual inhibitors of histone methyltransferases and DNA methyltransferases |
AU2016356884A1 (en) | 2015-11-16 | 2018-06-21 | Fundación Para La Investigación Médica Aplicada | Novel compounds as inhibitors of dna methyltransferases |
WO2018119208A1 (en) * | 2016-12-22 | 2018-06-28 | Global Blood Therapeutics, Inc. | Histone methyltransferase inhibitors |
-
2017
- 2017-12-21 WO PCT/US2017/067855 patent/WO2018119208A1/en unknown
- 2017-12-21 TW TW106145167A patent/TW201829386A/zh unknown
- 2017-12-21 EP EP17829543.2A patent/EP3558971B1/en active Active
- 2017-12-21 EP EP22153996.8A patent/EP4063358B1/en active Active
- 2017-12-21 JP JP2019531160A patent/JP7091336B2/ja active Active
- 2017-12-21 US US15/850,389 patent/US10829452B2/en active Active
- 2017-12-21 ES ES17829543T patent/ES2910108T3/es active Active
- 2017-12-22 AR ARP170103662A patent/AR110443A1/es unknown
-
2020
- 2020-11-04 US US17/089,239 patent/US11713299B2/en active Active
-
2022
- 2022-06-15 JP JP2022096439A patent/JP2022137047A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP4063358C0 (en) | 2024-05-22 |
JP2022137047A (ja) | 2022-09-21 |
US10829452B2 (en) | 2020-11-10 |
US11713299B2 (en) | 2023-08-01 |
TW201829386A (zh) | 2018-08-16 |
US20180186745A1 (en) | 2018-07-05 |
EP4063358A1 (en) | 2022-09-28 |
ES2910108T3 (es) | 2022-05-11 |
JP2020504716A (ja) | 2020-02-13 |
EP4063358B1 (en) | 2024-05-22 |
JP7091336B2 (ja) | 2022-06-27 |
US20210107876A1 (en) | 2021-04-15 |
EP3558971A1 (en) | 2019-10-30 |
EP3558971B1 (en) | 2022-02-23 |
WO2018119208A1 (en) | 2018-06-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR110443A1 (es) | Inhibidores de histona metiltransferasas | |
RU2018121834A (ru) | Новое соединение бифенила или его соль | |
CO5680412A2 (es) | Agonistas del receptor adrenergico etilamino beta 2 sustituido con amino | |
RU2448976C2 (ru) | Ингибиторы hcv/вич и их применение | |
ES2521596T3 (es) | Combinación del compuesto GlyT1 con antipsicóticos | |
CO6251260A2 (es) | Derivados de bifenilo conformacionalmente restringido para uso como inhibidores del virus de la hepatitis c. | |
CO6180449A2 (es) | Quinazolinonas y naftiridinonas que incluyen un grupo n-(bifenil-4-ilmetil-n-(piperidin-4-il)acetamida sustituida, utiles para el tratamiento de aterosclerosis | |
DOP2018000187A (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo | |
AR055592A1 (es) | Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace) | |
ES2669189T3 (es) | Compuestos de carbazol útiles como inhibidores del bromodominio | |
AR098666A1 (es) | Compuestos de biarilacetamida y sus métodos de uso | |
AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
EA201490287A1 (ru) | Новые замещенные производные индола в качестве модуляторов гамма-секретазы | |
PE20160608A1 (es) | Compuestos de quinolina selectivamente sustituida | |
AR082499A1 (es) | Compuestos utiles para trastornos del sistema nervioso, inflamatorios, estomacales y como analgesicos | |
PE20141075A1 (es) | 4-aril-n-fenil-1,3,5-triazin-2-aminas que contienen un grupo sulfoximina | |
RU2019143759A (ru) | Новое соединение бифенила или его соль | |
AR088029A1 (es) | Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central | |
AR081426A1 (es) | Derivados de pirazol inhibidores del receptor sigma | |
NZ630259A (en) | Heterobicyclic compounds as beta-lactamase inhibitors | |
AR083849A1 (es) | Antagonistas de mdm2 de espiro-oxindol | |
AR083069A1 (es) | Analogos de nucleotidos sustituidos | |
AR061564A1 (es) | Derivados de isoindoles, composiciones farmaceuticas y usos | |
AR075139A1 (es) | Compuestos biciclicos para la reduccion de la produccion de beta-amiloide | |
AR065811A1 (es) | Derivados de 2-amino-4h-imidazol-4-ona,composiciones farmaceuticas que los contienen y usos para el tratamiento de la enfermedad de alzheimer y otros trastornos neurodegenerativos. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |